Payment overview · 2025
General Payments
$314.56
7 reported records · 3 companies
Healthcare provider profile · identity verified
Michael E Wilson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ROCK SPRING, GA · NPI 1568455541
Verified facts
What the public records show
CMS Open Payments records show Michael E Wilson, M.D. received $314.56 in general payments during 2025 across 7 reported records.
AstraZeneca Pharmaceuticals LP accounted for 45.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nurtec Odt.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.03 | 45.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $114.60 | 36.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $55.93 | 17.8% | 3 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $314.56 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $126.49 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $114.60 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $55.93 | 3 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 73 |
| Gabapentin | Gabapentin | 235 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 63 |
| Atorvastatin Calcium | Atorvastatin Calcium | 221 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 208 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 195 | 27 |
| Alprazolam | Alprazolam | 186 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 53 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 151 | 17 |
| Allopurinol | Allopurinol | 137 | 37 |
| Diazepam | Diazepam | 136 | 25 |
| Omeprazole | Omeprazole | 136 | 40 |
| Ondansetron Odt | Ondansetron | 132 | 38 |
| Methocarbamol | Methocarbamol | 124 | 27 |
| Potassium Chloride | Potassium Chloride | 124 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 32 |
| Oxycodone Hcl | Oxycodone Hcl | 116 | 13 |
| Promethazine Hcl | Promethazine Hcl | 114 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 35 |
| Jardiance | Empagliflozin | 112 | 26 |
| Atenolol | Atenolol | 111 | 25 |
| Famotidine | Famotidine | 105 | 29 |
| Farxiga | Dapagliflozin Propanediol | 105 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 37 |
| Eliquis | Apixaban | 93 | 20 |
| Celecoxib | Celecoxib | 91 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 91 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 90 | 26 |
| Fluconazole | Fluconazole | 88 | 36 |
| Tramadol Hcl | Tramadol Hcl | 86 | 21 |
| Carvedilol | Carvedilol | 85 | 27 |
| Ezetimibe | Ezetimibe | 83 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 75 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 22 |
| Vascepa | Icosapent Ethyl | 73 | 20 |
| Montelukast Sodium | Montelukast Sodium | 70 | 19 |
| Trulicity | Dulaglutide | 69 | 11 |
| Estradiol | Estradiol | 68 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 68 | suppressed |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 68 | 12 |
| Glimepiride | Glimepiride | 65 | 18 |
| Prednisone | Prednisone | 65 | 35 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 18 |
| Raloxifene Hcl | Raloxifene Hcl | 62 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 13 |
| Nabumetone | Nabumetone | 59 | 22 |
| Lisinopril | Lisinopril | 57 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 16 |
| Myrbetriq | Mirabegron | 53 | 13 |
| Finasteride | Finasteride | 51 | 15 |
| Meclizine Hcl | Meclizine Hcl | 50 | 13 |
| Warfarin Sodium | Warfarin Sodium | 48 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 46 | 19 |
| Spironolactone | Spironolactone | 46 | 16 |
| Trazodone Hcl | Trazodone Hcl | 46 | 14 |
| Meloxicam | Meloxicam | 45 | 17 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Temazepam | Temazepam | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 29 |
| Digoxin | Digoxin | 42 | 11 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Ranolazine Er | Ranolazine | 42 | 11 |
| Pentoxifylline | Pentoxifylline | 41 | 11 |
| Furosemide | Furosemide | 40 | 13 |
| Irbesartan | Irbesartan | 40 | 23 |
| Telmisartan | Telmisartan | 40 | 16 |
| Cefuroxime | Cefuroxime Axetil | 39 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Torsemide | Torsemide | 39 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 38 | 13 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 37 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 35 | 14 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 23 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 34 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 12 |
| Azithromycin | Azithromycin | 33 | 26 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Sulindac | Sulindac | 32 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | 15 |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Metformin Hcl | Metformin Hcl | 25 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 23 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Lidocaine | Lidocaine | 22 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 17 |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Clonazepam | Clonazepam | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Pristiq | Desvenlafaxine Succinate | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Tymlos | Abaloparatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $314.56 · 7 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, GEMTESA, NURTEC ODT | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nurtec Odt play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error